BioSpace News Archive

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced it has received regulatory and ethics board approval of its Clinical Trial Application (“CTA”) to conduct a Phase 1 trial in the Netherlands for INM-755, a cannabinoid-based topical cream.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will present results from the Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma (rGBM) at the Inaugural Glioblastoma Drug Development Annual Summit

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, presented Phase 1 data yesterday from the healthy volunteer study of ALPN-101,

TScan Therapeutics recognizes its co-founders, Lea Hachigian Ph.D. and Tomasz Kula Ph.D., who were honored as healthcare pioneers in the Forbes 30 Under 30 list Class of 2020.

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of ArQule, Inc.

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Jay T. Backstrom, M.D., M.P.H., as Executive Vice President, Research and Development (R&D)

A team of medical experts from Israel’s Sheba Medical Center, Tel HaShomer is embarking on an emergency deployment to the Pacific island nation of Samoa following an urgent request from the World Health Organization (WHO) for humanitarian aid.

Oral presentation at the 12th Clinical Trials on Alzheimer’s Disease Conference (CTAD 2019) describes similarities in degenerative processes of Huntington’s and Alzheimer’s Disease

Data Suggest Protective Effects of Plinabulin on Bone Marrow Granulocyte-Monocyte Progenitor (GMP) and Common Lymphoid Progenitor (CLP) Cells

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the executive management team will webcast a review of Gritstone’s clinical programs, including preliminary immunogenicity and safety data from its ongoing Phase 1 GRANITE and Phase 1 SLATE clinical trials following an oral presentation at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress.